scholarly journals Bacillus subtilis: a universal cell factory for industry, agriculture, biomaterials and medicine

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Yuan Su ◽  
Chuan Liu ◽  
Huan Fang ◽  
Dawei Zhang
2013 ◽  
Vol 12 (1) ◽  
pp. 3 ◽  
Author(s):  
Jan Maarten van Dijl ◽  
Michael Hecker

2008 ◽  
Vol 7 (1) ◽  
pp. 10 ◽  
Author(s):  
Jessica C Zweers ◽  
Imrich Barák ◽  
Dörte Becher ◽  
Arnold JM Driessen ◽  
Michael Hecker ◽  
...  

2020 ◽  
Vol 3 (1) ◽  
Author(s):  
Christophe Michon ◽  
Choong-Min Kang ◽  
Sophia Karpenko ◽  
Kosei Tanaka ◽  
Shu Ishikawa ◽  
...  

AbstractA rare stereoisomer of inositol, scyllo-inositol, is a therapeutic agent that has shown potential efficacy in preventing Alzheimer’s disease. Mycobacterium tuberculosis ino1 encoding myo-inositol-1-phosphate (MI1P) synthase (MI1PS) was introduced into Bacillus subtilis to convert glucose-6-phosphate (G6P) into MI1P. We found that inactivation of pbuE elevated intracellular concentrations of NAD+·NADH as an essential cofactor of MI1PS and was required to activate MI1PS. MI1P thus produced was dephosphorylated into myo-inositol by an intrinsic inositol monophosphatase, YktC, which was subsequently isomerized into scyllo-inositol via a previously established artificial pathway involving two inositol dehydrogenases, IolG and IolW. In addition, both glcP and glcK were overexpressed to feed more G6P and accelerate scyllo-inositol production. Consequently, a B. subtilis cell factory was demonstrated to produce 2 g L−1scyllo-inositol from 20 g L−1 glucose. This cell factory provides an inexpensive way to produce scyllo-inositol, which will help us to challenge the growing problem of Alzheimer’s disease in our aging society.


Author(s):  
H. Pramastya ◽  
Y. Song ◽  
E.Y. Elfahmi ◽  
S. Sukrasno ◽  
W.J. Quax

2018 ◽  
Author(s):  
Haojie Cao ◽  
Julio Villatoro-Hernandez ◽  
Ruud Detert Oude Weme ◽  
Elrike Frenzel ◽  
Oscar P. Kuipers

AbstractBacillus subtilisis extensively applied as a microorganism for the high-level production of heterologous proteins. Traditional strategies for increasing the productivity of this microbial cell factory generally focused on the targeted modification of rate-limiting components or steps. However, the longstanding problems of limited productivity of the expression host, metabolic burden and non-optimal nutrient intake, have not yet been solved to achieve production strain improvements. To tackle this problem, we systematically rewired the regulatory networks of the global nitrogen and carbon metabolism by random mutagenesis of the pleiotropic transcriptional regulators CodY and CcpA, to allow for optimal nutrient intake, translating into significantly higher heterologous protein production yields. Using a β-galactosidase expression and screening system and consecutive rounds of mutagenesis, we identified mutant variants of both CcpA and CodY that in conjunction increased production levels up to 290%. RNA-Seq and electrophoretic gel mobility shift analyses showed that amino acid substitutions within the DNA-binding domains altered the overall binding specificity and regulatory activity of the two transcription factors. Consequently, fine-tuning of the central metabolic pathways allowed for enhanced protein production levels. The improved cell factory capacity was further demonstrated by the successfully increased overexpression of GFP, xylanase and a peptidase in the double mutant strain.HighlightsThe global transcription machinery engineering (gTME) technique was applied to build mutational libraries of the pleiotropic regulators CodY and CcpA inBacillus subtilisSpecific point mutations within the DNA-binding domains of CodY and CcpA elicited alterations of the binding specificity and regulatory activityChanges in the transcriptome evoked the reprogramming of networks that gear the carbon and nitrogen metabolismThe rewired metabolic networks provided a higher building block capacity for heterologous protein production by adjusting the nutrient uptake and channeling its utilization for protein overexpression


2020 ◽  
Vol 11 (1) ◽  
pp. 295-318 ◽  
Author(s):  
Kang Zhang ◽  
Lingqia Su ◽  
Jing Wu

Bacillus subtilis has become a widely used microbial cell factory for the production of recombinant proteins, especially those associated with foods and food processing. Recent advances in genetic manipulation and proteomic analysis have been used to greatly improve protein production in B. subtilis. This review begins with a discussion of genome-editing technologies and application of the CRISPR–Cas9 system to B. subtilis. A summary of the characteristics of crucial legacy strains is followed by suggestions regarding the choice of origin strain for genetic manipulation. Finally, the review analyzes the genes and operons of B. subtilis that are important for the production of secretory proteins and provides suggestions and examples of how they can be altered to improve protein production. This review is intended to promote the engineering of this valuable microbial cell factory for better recombinant protein production.


2017 ◽  
Vol 16 (1) ◽  
Author(s):  
Kosei Tanaka ◽  
Ayane Natsume ◽  
Shu Ishikawa ◽  
Shinji Takenaka ◽  
Ken-ichi Yoshida

2008 ◽  
Vol 74 (24) ◽  
pp. 7536-7545 ◽  
Author(s):  
Thijs R. H. M. Kouwen ◽  
Jean-Yves F. Dubois ◽  
Roland Freudl ◽  
Wim J. Quax ◽  
Jan Maarten van Dijl

ABSTRACT Disulfide bonds are important for the correct folding, structural integrity, and activity of many biotechnologically relevant proteins. For synthesis and subsequent secretion of these proteins in bacteria, such as the well-known “cell factory” Bacillus subtilis, it is often the correct formation of disulfide bonds that is the greatest bottleneck. Degradation of inefficiently or incorrectly oxidized proteins and the requirement for costly and time-consuming reduction and oxidation steps in the downstream processing of the proteins still are major limitations for full exploitation of B. subtilis for biopharmaceutical production. Therefore, the present study was aimed at developing a novel in vivo strategy for improved production of secreted disulfide-bond-containing proteins. Three approaches were tested: depletion of the major cytoplasmic reductase TrxA; introduction of the heterologous oxidase DsbA from Staphylococcus carnosus; and addition of redox-active compounds to the growth medium. As shown using the disulfide-bond-containing molecule Escherichia coli PhoA as a model protein, combined use of these three approaches resulted in secretion of amounts of active PhoA that were ∼3.5-fold larger than the amounts secreted by the parental strain B. subtilis 168. Our findings indicate that Bacillus strains with improved oxidizing properties can be engineered for biotechnological production of heterologous high-value proteins containing disulfide bonds.


Sign in / Sign up

Export Citation Format

Share Document